LexaGene Finalizes Design of Pneumonia Panel
Retrieved on:
Monday, November 1, 2021
Ethos, Fungus, CMY, Escherichia coli, Diagnosis, Proning, PCR, Hospital, Degenerative disease, TEM, LXG, MecA, Phycita, Infection, Histoplasma, Patient, Founder, TETS, SHV, Pneumonia, Staphylococcus, OTCQB, Enterobacterales, Time-invariant system, Enterobacter, CEO, Skin, Bacteria, Veterinarian, Animal, DVM, Teto, GLOBE, Tetje Mierendorf, Bordetella, Doctor of Philosophy, ONC, Ear, Vaccine, Pharmaceutical industry
In June 2021, LexaGene and Ethos Discovery partnered to develop a pneumonia panel to expand the utility of the MiQLab in veterinary diagnostics.
Key Points:
- In June 2021, LexaGene and Ethos Discovery partnered to develop a pneumonia panel to expand the utility of the MiQLab in veterinary diagnostics.
- Since then, LexaGene has been working closely with Ethos Discovery to design and validate a panel for rapidly determining the cause of pneumonia while simultaneously screening for antimicrobial resistance factors that should be taken into account when treating such infections in companion animals.
- As a next step, Ethos Discovery will conduct a clinical evaluation of the pneumonia panel on their purchased MiQLab.
- The MiQLab Pneumonia Panel includes 13 assays targeting bacteria and 4 assays targeting fungi, plus 19 assays targeting antimicrobial resistance genes.